Compare Mesoblast Limited (MESO) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Public Storage — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Public Storage trades at $285.55 (market cap $52.69B). The key difference: Public Storage is far larger — about 29.1× Mesoblast Limited's market cap, and Public Storage pays a 4.26% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Public Storage for 130 Days on average.
| MESO | PSA | |
|---|---|---|
Market Cap | $1.81B | $52.69B |
Volume | 240,620 | 975,662 |
Sector | Health | Real Estate |
52-Week High | $20.96 | $330.47 |
52-Week Low | $13.19 | $258.44 |
Typical Hold Time | 14 Days | 130 Days |
Enterprise Value | $1.89B | $66.96B |
Dividend Yield | — | 4.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Public Storage (PSA) trades at $285.52, down 0.12% on the day, with a bearish technical signal. The stock shows strong profitability with a 41.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent corporate actions include the completion of the Public Storage Canada acquisition and a $3.00 dividend declared for payment in October 2026. Analyst consensus is a Buy with a $328.33 price target, implying potential upside.
The outlook is mixed; strong fundamentals and analyst support suggest long-term value, but near-term technical weakness and fluctuating cash flows pose risks. Investors should weigh the high valuation multiples against the company's operational resilience and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
